MapLight Therapeutics, Inc. (MPLT) vs Myriad Genetics, Inc. (MYGN)
A side-by-side comparison of MapLight Therapeutics, Inc. and Myriad Genetics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MPLT
MapLight Therapeutics, Inc.
$9.36HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
MYGN
Myriad Genetics, Inc.
$4.37HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
Total return — MPLT vs MYGN
growth of $100 · dividends reinvested · last 1yMPLT -49.4% (-49.4%/yr)MYGN -41.3% (-41.3%/yr)MYGN compounded faster over this window
MPLT MYGN
MPLT vs MYGN: by the numbers
- •MYGN is the larger company ($413M vs $397M market cap).
- •Both run net losses; MPLT's is the smaller (0.00% vs -13.96% net margin).
Metrics side by side
Valuation
| Metric | MPLT | MYGN |
|---|---|---|
| P/S ratio | N/A | 0.51 |
| P/B ratio | 1.14 | 1.36 |
Profitability
| Metric | MPLT | MYGN |
|---|---|---|
| Gross margin | 0.00% | 68.83% |
| Operating margin | 0.00% | -12.22% |
| Net margin | 0.00% | -13.96% |
| ROE | -65.99% | -37.05% |
| ROIC | -69.35% | -19.13% |
Growth (annualized)
| Metric | MPLT | MYGN |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 9.70% |
| Total return CAGR (5Y) | N/A | -32.02% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.